KELLY STRATEGIC CRISPR & GENE EDITING TECHNOLOGY ETF - USD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.380 USD | -1.60% |
|
-2.45% | -25.75% |
Investment objective
XDNA seeks to track the total return performance, before
fees and expenses, of the Strategic CRISPR & Gene Editing
Technology Index, which measures the performance of
companies that specialize in CRISPR & DNA modification
systems, and technologies, for variety of applications
including basic biological research, development of
biotechnological products, and treatment of diseases as well
as next-generation sequencing that may be used at various
stages of a genome editing workflow.
Price
|
Change
|
5d. change
|
1st Jan change
|
Weight
| ||
|---|---|---|---|---|---|---|
| 528.87USD | -1.04% | +1.38% | -0.36% | 11.69% | ||
| 14.49USD | -1.09% | -4.73% | -52.48% | 11.15% | ||
| 51.14USD | -0.20% | +0.59% | -18.31% | 8.55% | ||
| 26.02USD | +0.15% | -4.34% | -4.41% | 8.03% | ||
| 2.035USD | -6.22% | -7.50% | -64.49% | 6.97% | ||
| 9.410USD | +0.86% | +0.86% | +180.06% | 4.87% | ||
| 1.990USD | +0.51% | -9.55% | -80.36% | 4.83% | ||
| 176.46USD | -2.78% | -3.62% | +13.87% | 4.81% | ||
| 3.190USD | +1.92% | -3.33% | -64.00% | 4.71% | ||
| 6.630USD | -5.42% | +14.71% | -52.44% | 4.13% | ||
More news
In partnership with
Description
| US48817R7061 | |
|---|---|
| Total Expense Ratio | 0.78% |
| Asset Class | Equities |
| Sector | |
| Size | |
| Currency | |
| Provider | |
| Underlying | Strategic CRISPR & Gene Editing Technology Index NR - USD |
Features and characteristics
| Dividend Policy | Distribution |
|---|---|
| Replication Method | Physique |
| Jurisdiction | |
| Replication Model | |
| Date of creation |
2022-01-11
|
| Geographical Focus |
AuM evolution ( 2023-10-30 )
| AuM (EUR) | 2 M€ |
|---|---|
| AuM 1M | 2 M€ |
| AuM 3 months | 2 M€ |
| AuM 6 months | 2 M€ |
| AuM 12 months | 5 M€ |
- Stock Market
- ETF
- XDNA ETF